Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Story2
Netcapital hires Adeptus Partners to re-audit five years of accounts after earlier statements were declared unreliable
SEC filings show Netcapital has appointed a new auditor to re-audit fiscal years 2022 to 2026 and remains behind on its Nasdaq filings.
GoodRx says first-half 2026 revenue was understated by up to $29.8 million, plans to restate accounts
An 8-K filed on 2 November 2026 shows GoodRx Holdings' Audit and Risk Committee concluded on 27 October 2026 that the company's financial statements for the quarters ended 31 March and 30 June 2026 should no longer be relied upon because of understated Pharma Direct revenue.
Company or person17
RELIANCE, INC.
Company
Reliance Global Group, Inc.
Company
RELIABILITY INC
Company
Reddit, Inc.
Company
Rezera Inc.
Company
RESMED INC
Company
REED'S, INC.
Company
TPG RE Finance Trust, Inc.
Company
REVVITY, INC.
Company
Cerence Inc.
Company
RXO, Inc.
Company
RPC INC
Company
NNN REIT, INC.
Company
RenovoRx, Inc.
Company
Rezolute, Inc.
Company
REALLOYS INC.
Company
All In FutureTech Alliance, Inc.
Company
Primary record11
Mount Logan Capital Inc. filed 8-K
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On November 3, 2026, the board of directors of Mount Logan Capital Inc. (the “ Company ”) appointed Brando
Sidus Space Inc. filed 8-K
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) Non-Reliance Determination On November 2, 2026, the Audit Committee (the “Audit Committee”) of t
NB Bancorp, Inc. filed 8-K
Item 1.01 Entry into Material Definitive Agreement. On November 6, 2026, NB Bancorp, Inc. (the “Company”), the holding company of Needham Bank (the “Bank”), entered into a Subordinated Note Purchase Agreement (the “Subor
Silo Pharma, Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On November 5, 2026, Silo Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (“th
GREIF, INC filed 8-K
Item 2.02. Results of Operations and Financial Condition. On November 3, 2026, Greif, Inc. (the “Company”) issued a press release (the “Earnings Release”) announcing the financial results for its fourth quarter and fisca
GeoVax Labs, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Termination of President and Chief Executive Officer On Nove
HeartSciences Inc. filed 8-K
Item 8.01 Other Events. As previously disclosed, HeartSciences Inc., a Texas corporation (“ HeartSciences ” or the “ Company ”), entered into an Agreement and Plan of Merger, dated as of June 23, 2026 (as amended on July
Ubiquiti Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 6, 2026, Ubiquiti Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy
First Breach, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On November 3, 2026, First Breach Inc. (the “Company”) issued a press release announcing certain supply agreements and equipment additions in support of the Company’s ammunition produ
Sino Green Land Corp. filed 8-K
Item 2.01. Completion of Acquisition or Disposition of Assets. As previously disclosed, Sino Green Land Corporation (the “Company”) entered into a stock purchase agreement (the “Hi-Quality SPA”) with Cheng You (the “Sell
STURM RUGER & CO INC filed 8-K
Item 7.01 Regulation FD Disclosure On November 4, 2026, the Company hosted its post-earnings release conference call and webcast to discuss our third quarter 2026 financial results. The transcript of the conference call